Targeted Therapy in Hepatocellular Carcinoma

Table 1

Agent	Study	Phase	Comparator arm	No. of patients	Response rate	TTP; (median months)	OS; (median months)	AEs
Sorafenib	Abou-Alfa et al. [35]	II	—	137	34% SD; 8% PR/MR	—	9.2	HFS, diarrhea, fatigue
	SHARP trial Llovet et al. [38]	III	Vs placebo	602	2% PR; No CR	5.5 versus 2.8	10.7 versus 7.9	HFS (21%), diarrhea (39%)
	Cheng et al. [39]	III	Vs placebo	271	—	2.8 versus 1.4	6.5 versus 4.2	HFS (45%), diarrhea (26%), rash (20%), fatigue (20%)
Sorafenib + TACE	START trial Chung et al. [41]	II	—	50 (evaluable)	36% CR; 60% PR/SD	—	—	—
Sorafenib + doxorubicin	Abou-Alfa et al. [42]	II	Vs doxorubicin	96	—	6.4 versus 2.8	13.7 versus 6.5	Same both arms
Bevacizumab	Siegel et al. [43]	II	—	46	13% PR		53% (1 yr) 28% (2 yr) 23% (3 yr)	Hypertens ion (15%), thrombos is (6%)
Bevacizumab + gemcitabine + oxaliplatin	Zhu et al. [44]	II	—	30 (evaluable)	20% RR; 27% SD	—	9.6	—
Bevacizumab + capecitabine + oxaliplatin	Sun et al. [45]	II	—	30 (evaluable)	13% PR; 77% SD	4.5	10.3	—
Bevacizumab + capecitabine	Hsu et al. [46]	II	—	45	9% RR; 52% CR/PR/SD	2.7 (PFS)	5.9	HFS 9%; BGIT 9%
Bevacizumab + erlotinib	Thomas et al. [47]	II	—	40	—	9 (PFS)	15.6	BGIT 13%, fatigue 20%, hypertens ion 15%
Sunitinib	Zhu et al. [48]	II	—	34	50% SD	4.1	—	—
	Faivre et al. [49]	II	—	37	2% PR; 35% SD	3.7 (PFS)	8	Significant 4 deaths,; trial stopped
ABT-69	Toh et al. [50]	II	—	44 (34 evaluable)	8.7% (23 CP A pts)	3.7	9.8	Mostly mild mod
Erlotinib	Philip et al. [51]	II	—	38	9% PR	32% (6 months PFS)	13	—
	Thomas et al. [52]	II	—	40	—	28% (6 months PFS)	3.3	—

RR: overall response rate, MR: minor response, PR: partial response, SD: stable disease, CR: complete response, PFS: progression-free survival, TTP: time to progression, OS: overall survival, AEs: adverse events, HFS: hand-foot syndrome, BGIT: bleeding gastrointestinal tract, CP A: Child Pugh A.